• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Viking Thera (NQ: VKTX )

    65.07 +0.45 (+0.70%)
    Streaming Delayed Price Updated: 12:11 PM EDT, Oct 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Viking Thera

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    17 18 Next >
    Viking Therapeutics Gives Investors Another Reason to Remain Bullish on Its Future
    Viking recently announced the results of an early-stage clinical trial for VK0214. 
    Via The Motley Fool
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade
    The analyst is closely watching MariTide, a potential monthly injection to treat obesity. 
    Via Investor's Business Daily
    Where Will Viking Therapeutics Be in 5 Years?
    We could be witnessing the birth of a major player in the biotech industry. 
    Via The Motley Fool
    Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit Therapeutics
    It's hard to go wrong with either company, but one is more appealing. 
    Via The Motley Fool
    Here's How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 5 Years
    Via Benzinga
    Viking Therapeutics Unusual Options Activity
    Via Benzinga
    $100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth This Much Today
    Via Benzinga
    The Ultimate Biotech Stock to Buy With $100 Right Now
    This company is operating in one of today's hottest markets. 
    Via The Motley Fool
    Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
    The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns. 
    Via Benzinga
    Viking Therapeutics Reveals Encouraging Data From Genetic Disorder Drug Study, Analyst Says Focus On Orphan Disease Broadens Viking's Potential Revenue Streams
    Viking Therapeutics' VK0214 Phase 1b trial in X-ALD patients showed significant reductions in VLCFAs and other lipids, while demonstrating safety. Analyst sees potential revenue upside with continued... 
    Via Benzinga
    2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street Analysts
    The investment bank analysts who follow these stocks think they can soar even further, with some caveats. 
    Via The Motley Fool
    As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
    Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention. 
    Via Investor's Business Daily
    Viking Therapeutics Unusual Options Activity For September 24
    Via Benzinga
    What the Options Market Tells Us About Viking Therapeutics
    Via Benzinga
    Why Viking Therapeutics Stock Topped the Market Today
    An analyst waxed bullish on the company's leading pipeline program. 
    Via The Motley Fool
    Is Viking Therapeutics Stock a Buy?
    The company is in the spotlight for one of its programs, but it's got others that also have promise. 
    Via The Motley Fool
    Better Rising Biotech: Viking Therapeutics vs. Summit Therapeutics
    One of them is performing much better than the other this year. 
    Via The Motley Fool
    Why Viking Therapeutics Stock Was So Healthy on Wednesday
    Hardly for the first time, a pundit following the company waxed bullish on its future. 
    Via The Motley Fool
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    US Stocks Stall, Gold Updates Record Highs, Tesla Rallies: What's Driving Markets Monday?
    Wall Street kicked off the week on a cautious note, with major indexes trading relatively flat as investors seek more clarity on the economic and political landscape. 
    Via Benzinga
    Amgen vs. Viking Therapeutics: What's the Better GLP-1 Stock to Buy?
    These two stocks could be rivals in the intense GLP-1 space in the future. 
    Via The Motley Fool
    Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today
    The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout. 
    Via The Motley Fool
    Jim Cramer: Viking Therapeutics Has 'Many Ships Coming In'
    Viking Therapeutics received an Overweight rating and a December 2025 price target of $80 from JPMorgan analysts. 
    Via Benzinga
    This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments
    Terns has a modest market cap of less than $800 million, and its possible upside could be massive. 
    Via The Motley Fool
    Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
    These biotech stocks have what it takes to be the biggest winners through the rest of the decade and beyond. 
    Via The Motley Fool
    1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)
    Telemedicine once seemed like it was going to revolutionize healthcare. 
    Via The Motley Fool
    Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now.
    Terns Pharmaceuticals just proved that it's competitive in the weight loss field. 
    Via The Motley Fool
    Stock Market Rally Revives; Apple iPhone 16, Nvidia, Oracle, Adobe In Focus: Weekly Review
    The major indexes reclaimed key levels and many leaders flashed buy signals. 
    Via Investor's Business Daily
    These 2 Biotech Stocks Are Set to Soar
    Innovative drugmakers developing treatments for conditions with high unmet needs can produce lucrative wins. 
    Via The Motley Fool
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    17 18 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.